Abstract:
Background: The emergence of multidrug-resistant strains of Mycobacterium tuberculosis (MTB) represents a global public health challenge. The challenge in managing tuberculosis lies in the rapid diagnosis of these resistances. The objective of this study was to determine the proportion of MTB resistant to rifampicin.
Methods: This was a retrospective cross-sectional study conducted from January to December 2024. The study population consisted of outpatients and inpatients at Angré University Hospital suspected of having tuberculosis who were tested for rifampicin-resistant Mycobacterium tuberculosis using GeneXpert MTB/RIF (Cepheid). Data were collected from laboratory records and analyzed using Epi Info software.
Results: The study population consisted of 615 patients and included (305) 49.59% men and (310) 50.41% women, with a sex ratio (M/F) of 0.9. The 30-40 age group was the largest (131) 21.30%, with an average age of 44.9 ± 26.6. Gastric fluid was the most commonly collected sample (339) 55.12%, followed by sputum (182) 29.59%. 527 (85.69%) of patients were newly screened and 58 (9.43%) were being monitored. 45 (8.02%) were positive for Mycobacterium tuberculosis, with 11 (24.44%) sensitive to the rpoB gene and 9 (20%) with indeterminate results.
Conclusion: MTB RIF resistance was found in 24.44%. A strategy for monitoring these patients should be put in place to reduce the spread of this resistance.
Biography:
Dr. Som Dipielte Estelle Mireille, a medical biologist, quality auditor, and epidemiologist, and a FETP graduate and mentor. I currently work at the Angré University Hospital (CHU), where I participated in the accreditation of laboratories according to the ISO 15189 :2022 standard.I participated in the 7th International Conference on Infection Prevention and Control, held in Switzerland in 2023, where I presented a poster titled “Seroprevalence of SARS-CoV-2 in Blood Transfusion Centers in Côte d’Ivoire.”
Last year, I presented “Analysis of the Acute Flaccid Paralysis Database in Côte d’Ivoire from 2021 to 2023” at the 9th World Congress on Infectious Diseases.
In April of this year, I participated in the Congress of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID), which took place from April 17 to 27 in Munich, Germany.
